Connection
Charles Dinarello to Adalimumab
This is a "connection" page, showing publications Charles Dinarello has written about Adalimumab.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.226 |
|
|
|
-
Kanni T, Argyropoulou M, Spyridopoulos T, Pistiki A, Stecher M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 Targeting IL-1a for Moderate to Severe Hidradenitis Suppurativa Not Eligible for Adalimumab: A Randomized Study. J Invest Dermatol. 2018 04; 138(4):795-801.
Score: 0.132
-
Dinarello CA. Differences between anti-tumor necrosis factor-alpha monoclonal antibodies and soluble TNF receptors in host defense impairment. J Rheumatol Suppl. 2005 Mar; 74:40-7.
Score: 0.055
-
Kanni T, Argyropoulou M, Dinarello CA, Simard J, Giamarellos-Bourboulis EJ. MABp1 targeting interleukin-1a in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. Clin Exp Dermatol. 2021 Jan; 46(1):162-163.
Score: 0.040